Georgia Recovers $540K from Settlement with Pharmaceutical Company Wyeth Over Allegations of Off-Label Marketing
Attorney General Sam Olens announced today that Georgia has joined with other states and the federal government in a $491 million dollar settlement to resolve civil and criminal allegations that Wyeth Pharmaceuticals, Inc. (Wyeth), a Delaware corporation headquartered in Collegeville, Pa., promoted the sale and use of Rapamune for uses for which it had not been approved by the Federal Drug Administration (FDA). Rapamune is a FDA approved kidney transplant drug which is prescribed to prevent the body from rejecting a donor organ that has been transplanted into the body. The total portion of the settlement amount recovered by Georgia is $540,498.11.
Action Details
- Date:August 1, 2013
- Agency:Georgia Attorney General
-
Enforcement Types:
- State Enforcement Agencies